Efficacy and safety of diquafosol sodium eye drops for children with dry eye wearing orthokeratology lens
10.3980/j.issn.1672-5123.2026.3.03
- VernacularTitle:地夸磷索钠滴眼液对配戴角膜塑形镜的干眼患儿的疗效及安全性
- Author:
Zhongming LI
1
;
Yongchuan HE
1
;
Mengyao WANG
1
;
Ying LIU
1
;
Yi REN
1
Author Information
1. Chongqing Aier Children's Eye Hospital, Chongqing 400020, China
- Publication Type:Journal Article
- Keywords:
dry eye disease;
orthokeratology;
myopia;
children;
diquafosol sodium;
randomized controlled trial
- From:
International Eye Science
2026;26(3):375-382
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To evaluate the efficacy and safety of 3% diquafosol sodium eye drops in children wearing orthokeratology lenses and with dry eye disease(DED)or at risk of DED.METHODS: Randomized controlled trials. Children with DED or at risk of DED were randomly assigned in a 1:1 ratio to receive either 3% diquafosol sodium eye drops 6 times daily or a blank control at Chongqing Aier Children's Eye Hospital from November 2023 to November 2024. The primary endpoint was the change in the Dry Eye Questionnaire-5(DEQ-5)score from baseline at 12 wk. Secondary assessments included non-invasive breakup time(NIBUT), tear meniscus height, Schirmer's test, corneal fluorescein staining score, and axial length.RESULTS: A total of 80 participants(80 eyes)were enrolled(40 in each group), the average age of the participants was 11.11±1.88 years, with 43 females(54%)and 37 males(46%), and all completed the trial. After 12 wk, the DEQ-5 scores for the diquafosol sodium group and the blank control group were 1.88±2.02 and 2.88±2.79, respectively(P=0.079). The diquafosol sodium group demonstrated a significant improvement in DEQ-5 dryness symptom scores(-0.33±0.66 vs. 0.05±0.81, P=0.023)and NIBUT(6.18±3.73 vs. -1.09±4.40 s, P<0.001)at 12 wk. Additionally, the diquafosol sodium group showed no axial length elongation, in contrast to the blank control group, which exhibited elongation(0.00±0.08 vs. 0.05±0.10 mm, P=0.013). No other significant differences were found in the secondary endpoints. No adverse events occurred during the trial.CONCLUSION: Although no statistically significant improvements were noted in the overall DEQ-5 scores, the 3% diquafosol sodium eye drops significantly improved dryness symptoms and NIBUT when compared to the blank control group.
